To further ascertain the influence of cellular senescence after DEX cotreatment in NSCLC in vivo, SA-β-gal staining and immunohistochemistry were carried out to analyze SA-β-gal activity and expressions of p53 and p65 in tumor tissues from 56 patients with NSCLC. The gene discussed is TP53; the disease is non-small cell lung carcinoma.